Dr. Gerard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Longwood Ave
Boston, MA 02115Phone+1 617-355-1900Fax+1 617-730-0084
Education & Training
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1986 - 1988
- Harvard Medical SchoolFellowship, 1985 - 1987
- Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1985 - 1986
- Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 1985, MD
- Research Institute of Scripps ClinicPost-Doctoral Fellowship, 1981 - 1981
- University of CaliforniaM.S., Ph.D, Chemistry, 1981
- University of CaliforniaFellowship, 1977 - 1980
- University of ConnecticutB.A, 1976
Certifications & Licensure
- MA State Medical License 1987 - 2019
Awards, Honors, & Recognition
- RJR Nabisco Faculty Scholar Harvard Medical School (1989-1992), 1992
- American Society for Clinical Investigation 1992
- Elected Member The American Society for Clinical Investigation, 1992
- Join now to see all
Publications & Presentations
PubMed
- 511 citationsRequirement of the Chemokine Receptor CXCR3 for Acute Allograft RejectionWayne W. Hancock, Bao Lu, Wei Gao, Vilmos Csizmadia, Kerrie L. Faia
The Journal of Experimental Medicine. 2000-11-20 - 979 citationsInduced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming.Alfonso Martín-Fontecha, Lindy L. Thomsen, Sara Brett, Craig Gerard, Martin Lipp
Nature Immunology. 2004-12-01 - 182 citationsCCR3 is a target for age-related macular degeneration diagnosis and therapyAtsunobu Takeda, Judit Z. Baffi, Mark E. Kleinman, Won Gil Cho, Miho Nozaki
Nature. 2009-07-09
Journal Articles
- Molecular aspects of the serum chemotactic factors.GERARD C, Chenoweth DE, Hugli TE, J Reticuloendothel Soc 1979; 26(Suppl): 711-8
- C5a: a mediator of chemotaxis and cellular release reactions.GERARD C, Hugli TE, Kroc Found Ser 1981; 14: 147-160
- Human C5a anaphylatoxin: gene synthesis, expression, and recovery of biologically active material from Escherichia coli.Franke AE, Andrews GC, Stimler-Gerard NP, GERARD C, Showell HJ, Methods Enzymol 1988; 162: 653-668
- Join now to see all
Books/Book Chapters
Lectures
- NEP Knockout Mouse.1st International Symposium of Cardiovascular Endocrinology and Metabolism, Kyoto, Japan
- Early Disease-How does it Start?Cystic Fibrosis Foundation, Williamsburg Conference, Williamsburg, VA
- HIV and Chemokines.NIH, Washington, DC
- Join now to see all
Press Mentions
- Protective Role of C3aR (C3a Anaphylatoxin Receptor) Against Atherosclerosis in Atherosclerosis-Prone MiceJuly 30th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: